Stock research
Marsh & McLennan Companies, Inc. MRSH
- Revenue
- $27.0B
- FY ending 2025-12-31
- Net income
- $4.2B
- Diluted EPS
- $8.43
- Net margin
- 15.4%
Audited figures from Marsh & McLennan Companies, Inc.'s SEC XBRL filings, FY ending 2025-12-31.
Delayed Cboe One market data via TradingView. It may differ from primary-exchange or consolidated quotes.
MRSH key financials
Reported figures from Marsh & McLennan Companies, Inc.'s audited annual filing, pulled directly from SEC XBRL data rather than a third-party terminal. Each row links to the filing it came from.
| Metric | Value | Period | Source |
|---|---|---|---|
| Revenue | $27.0B | 2025-01-01 – 2025-12-31 | SEC filing |
| Net income | $4.2B | 2025-01-01 – 2025-12-31 | SEC filing |
| Operating cash flow | $5.3B | 2025-01-01 – 2025-12-31 | SEC filing |
| Diluted EPS | $8.43 | 2025-01-01 – 2025-12-31 | SEC filing |
| Net margin | 15.4% | 2025-01-01 – 2025-12-31 | SEC filing |
| Shares outstanding | 484M | As of 2026-02-05 | SEC filing |
Values are as tagged by the issuer in XBRL. Revenue for banks and insurers is net of interest expense where that is the reported line. Fiscal years that do not follow the calendar are shown by their period-end date. No price, market cap, or valuation multiple is shown because Yield Theory does not republish unlicensed market data.
What moves MRSH
Marsh & McLennan Companies, Inc. sits in Financials. Banks, insurers, asset managers, and exchanges — the plumbing of capital markets, geared directly to interest rates and credit. The forces that matter most for the sector — and therefore for MRSH — are:
- ◆The shape of the yield curve and net interest margins
- ◆Credit quality and loan-loss provisions
- ◆Regulation and capital requirements
- ◆Deal activity and market volatility
Congressional trading in MRSH
| Politician | Trade date | Type | Owner | Amount | Source |
|---|---|---|---|---|---|
| Kevin Hern | 2026-08-24 | Sale | Joint | $1,001 - $15,000 | Filing #20035326 |
| Alan Armstrong | 2026-03-27 | Sale | Self | $1,001 - $15,000 | Filing #fda235b3-bad7-4637-8fa1-053f354d929c |
Congressional disclosures are delayed, range-based records—not real-time signals or proof of motive. See the source-linked tracker for scope and limitations.
Members-only research
What members are reading this month
Sep 22, 2026
Meta jumped 11%. What must happen next to justify the price?A member research report on Meta’s AI rally: Muse, subscription economics, the cash-flow burden, legal costs and the earnings assumptions behind the new price.
Feb 23, 2026
Newmont and the gap between a gold rally and shareholder cashA February 23, 2026 historical cutoff tests whether portfolio simplification and cost control could turn stronger gold economics into cash.
The thesis, the numbers behind it, and what would break it. Full access is $15 a month.
Read the full researchHow Yield Theory covers MRSH
MRSH intersects several of the themes in every Yield Theory issue. We don't chase headlines on individual tickers — we track where capital is rotating and explain what it means for the names in its path.
Explore this industry
Compare MRSH with similar companies
More Financials stocks
MRSH — frequently asked questions
What sector is MRSH in?
Marsh & McLennan Companies, Inc. is classified in the Financials sector and trades on the NYSE.
Do members of Congress trade MRSH?
The current verified House and Senate snapshot contains 2 transaction rows for MRSH. Each row below links to the original filing.
Is MRSH a good investment?
We don't publish one-line buy/sell ratings. Yield Theory members get the full macro thesis, catalysts, and risks behind every name we cover, so you can decide with conviction. This page is research, not investment advice.
This page is independent research and educational information, not investment advice or a recommendation to buy or sell any security. Company facts are compiled from public sources. Do your own research.
See whether the MRSH thesis still holds.
This page is company context and filings. Members get one sourced monthly call, a weekly evidence check, and the breakpoint written in advance. $15/month or $150/year.
Members-only research
$15/mo or $150/yr · cancel future renewals anytime · sources included